title: Staged pathology in Parkinson's disease.
abstract: There has been a tremendous development since a regional progression of pathology in subjects with Lewy bodies (LB) was initially proposed 30 years ago. The entity of dementia with Lewy bodies has been acknowledged, the main protein constituent of LBs--aggregated α-synuclein (αS)--has been identified and a stepwise progression of the pathology has been reported. Implementation of the staging strategies published provides a common ground for handling a case with a suspected α-synucleinopathy. It is always important to state the staging strategy implemented while assessing a case, as the strategy applied might influence both the reported stage of LB pathology and, ultimately, the final diagnosis of the patient.
authors.affiliation: Department of Pathology and Cytology, Uppsala University Hospital, Uppsala, Sweden; Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden. Electronic address: irina.alafuzoff@igp.uu.se.
authors.forename: Irina
authors.initials: I
authors.lastname: Alafuzoff
authors.forename: Laura
authors.initials: L
authors.lastname: Parkkinen
mesh_terms: D018450:Disease Progression; D006801:Humans; D016631:Lewy Bodies / Q000378:metabolism*; D010300:Parkinson Disease / Q000378:metabolism / Q000473:pathology*; D051844:alpha-Synuclein / Q000378:metabolism*
chemical_list: D051844:alpha-Synuclein
keywords: Neuropathology; Staging; α-Synuclein